Loading...
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler, M Mahlberg, R Heinemann, V Obermannová, R Kubala, E Melichar, B Weinmann, A Scigalla, P Tesařová, M Janda, P
Moehler, M
Mahlberg, R
Heinemann, V
Obermannová, R
Kubala, E
Melichar, B
Weinmann, A
Scigalla, P
Tesařová, M
Janda, P
Citations
Altmetric:
Abstract
This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).
Description
Date
2016-06-02
Publisher
Collections
Files
Loading...
s10120-016-0618-0.pdf
Adobe PDF, 450.63 KB
Keywords
Type
Article
Citation
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. 2016: Gastric Cancer